Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mecbotamab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Bone cancer; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors BioAtla

Most Recent Events

  • 07 Nov 2025 According to a Bioatla media release, data from the trial were presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 5-9, 2025, in National Harbor, Maryland.
  • 07 Nov 2025 Results presented in the BioAtla Media Release
  • 23 Sep 2025 Actual primary completion date changed from 30 Jan 2025 to 8 Jan 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top